Hoping that isn't the case when the 10K gets released.
Hoping that isn't the case when the 10K gets released. There has to be some new revenues in there. It will still be a negative net though, but as long as revenues start going up, we should see some buying pressure. I think the market keeps hearing of all these deals and the great numbers, but need to start seeing the flower grow from all the seeds planted.
If the darn market would tumble, I could get out of my TVIX which has killed my portfolio, and then buy these nice cheap shares of GNBT.
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Revolutionizing Cloud Mining with BCC Mining Cloud mining has witnessed significant advancements, particularly with the recent introduction of BCC Mining's mobile app. This development marks a new era for cryptocurrency enthusiasts, making it easier than ever to participate in mining activities. Users now have the flexibility to manage their mining operations from...
Continue Reading
CEFALY Introduces the Pregnancy Registry for Migraine Treatment Medical device company CEFALY Technology has recently announced the introduction of the CEFALY Pregnancy Registry, a research initiative aimed at assessing the safety of external trigeminal nerve stimulation (eTNS) for migraine treatment during pregnancy. The Challenge of Managing Migraines During Pregnancy...
Continue Reading
Velocity MSC Expands Offerings with Innovative 5G Communication Solution Velocity MSC, a trusted name in technological solutions, has announced an exciting addition to its service lineup. The company has incorporated DataRemote's advanced 90X1 5G Plain Old Telephone Service (POTS) replacement solution into its existing offerings. This innovative solution aligns with...
Continue Reading
Interleukin-23 Inhibitors Market Overview The interleukin-23 inhibitors market is currently experiencing significant growth, fueled by the escalating prevalence of autoimmune diseases such as psoriasis and inflammatory bowel disease. With innovations in biologics and increasing acceptance of targeted therapies, the demand for these treatments continues to surge....
Continue Reading
Hexagon Plans Spin-Off for Enhanced Focus and Growth Hexagon AB is embarking on an exciting journey towards the spin-off of its Asset Lifecycle Intelligence (ALI) division and associated businesses. This significant decision, made by the Board of Directors, aims to separate ALI into a new entity that will allow both Hexagon and the new organization, referred to as NewCo,...
Continue Reading
